HK1187892A1 - 硫代酰胺化合物及生產該化合物、 -氨乙基- -二噁烷- -基 乙酸酯衍生物和阿托伐他汀的方法 - Google Patents

硫代酰胺化合物及生產該化合物、 -氨乙基- -二噁烷- -基 乙酸酯衍生物和阿托伐他汀的方法

Info

Publication number
HK1187892A1
HK1187892A1 HK14100943.2A HK14100943A HK1187892A1 HK 1187892 A1 HK1187892 A1 HK 1187892A1 HK 14100943 A HK14100943 A HK 14100943A HK 1187892 A1 HK1187892 A1 HK 1187892A1
Authority
HK
Hong Kong
Prior art keywords
compound
atorvastatin
aminoethyl
dioxane
producing
Prior art date
Application number
HK14100943.2A
Other languages
English (en)
Inventor
柴崎正勝
熊谷直哉
Original Assignee
公益財團法人微生物化學研究會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 公益財團法人微生物化學研究會 filed Critical 公益財團法人微生物化學研究會
Publication of HK1187892A1 publication Critical patent/HK1187892A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/42—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK14100943.2A 2011-02-21 2014-01-29 硫代酰胺化合物及生產該化合物、 -氨乙基- -二噁烷- -基 乙酸酯衍生物和阿托伐他汀的方法 HK1187892A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011035006A JP5705580B2 (ja) 2011-02-21 2011-02-21 チオアミド化合物、チオアミド化合物の製造方法、［（４ｒ，６ｒ）−６−アミノエチル−１，３−ジオキサン−４−イル］アセテート誘導体の製造方法、及びアトルバスタチンの製造方法
PCT/JP2012/053323 WO2012114926A1 (ja) 2011-02-21 2012-02-14 チオアミド化合物、チオアミド化合物の製造方法、［（４ｒ，６ｒ）－６－アミノエチル－１，３－ジオキサン－４－イル］アセテート誘導体の製造方法、及びアトルバスタチンの製造方法

Publications (1)

Publication Number Publication Date
HK1187892A1 true HK1187892A1 (zh) 2014-04-17

Family

ID=46720708

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14100943.2A HK1187892A1 (zh) 2011-02-21 2014-01-29 硫代酰胺化合物及生產該化合物、 -氨乙基- -二噁烷- -基 乙酸酯衍生物和阿托伐他汀的方法

Country Status (7)

Country Link
US (1) US8785690B2 (zh)
EP (1) EP2679580B1 (zh)
JP (1) JP5705580B2 (zh)
CN (1) CN103384659B (zh)
HK (1) HK1187892A1 (zh)
IL (1) IL228027A (zh)
WO (1) WO2012114926A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5986872B2 (ja) * 2012-10-05 2016-09-06 公益財団法人微生物化学研究会 化合物、該化合物の製造方法、アセテート誘導体の製造方法、及びアトルバスタチンの製造方法、並びに不斉配位子の回収方法
CN105503815A (zh) * 2014-09-22 2016-04-20 兰州大学 一种立普妥合成中间体的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CN1127503C (zh) * 2000-12-08 2003-11-12 中国科学院上海有机化学研究所 （r）－2－[3－（2－n－邻苯二甲酰亚胺基乙基）－4，5－二氢－5－异噁唑基]－乙酸、合成及用途
CZ292221B6 (cs) * 2001-06-29 2003-08-13 Léčiva, A. S. Způsob výroby (4R,6R) terc-butyl[6-(2-aminoethyl)-2,2-dimethyl[1,3]dioxan-4-yl]acetátu a meziproduktů pro jeho výrobu
AU2003258187A1 (en) 2002-08-09 2004-02-25 Codexis, Inc. Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives
GB0317393D0 (en) * 2003-07-25 2003-08-27 Avecia Ltd Process and compounds
WO2006134482A1 (en) * 2005-06-16 2006-12-21 Pfizer Inc. Process for producing atorvastatin, pharmaceutically acceptable salts thereof and intermediates thereof
DE602005014686D1 (de) * 2005-09-09 2009-07-09 Pfizer Science & Tech Ltd Herstellung eines atorvastatin-zwischenprodukts
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
WO2007034909A1 (ja) * 2005-09-22 2007-03-29 Kaneka Corporation （３ｒ，５ｒ）－７－アミノ－３，５－ジヒドロキシヘプタン酸誘導体の製造法
CN101805279A (zh) * 2010-01-22 2010-08-18 绍兴民生医药有限公司 阿托伐他汀钙的制备方法

Also Published As

Publication number Publication date
US8785690B2 (en) 2014-07-22
US20130338375A1 (en) 2013-12-19
EP2679580A4 (en) 2015-09-09
EP2679580B1 (en) 2017-08-09
IL228027A (en) 2015-05-31
CN103384659B (zh) 2015-11-25
JP2012171904A (ja) 2012-09-10
IL228027A0 (en) 2013-09-30
JP5705580B2 (ja) 2015-04-22
EP2679580A1 (en) 2014-01-01
WO2012114926A1 (ja) 2012-08-30
CN103384659A (zh) 2013-11-06

Similar Documents

Publication Publication Date Title
EP2628400A4 (en) Cigarette and method for manufacturing same
EP2679592A4 (en) NEW HETEROCYCLIC COMPOUND, PROCESS FOR PRODUCING INTERMEDIATE PRODUCTS THEREOF AND USE THEREOF
PT2639234T (pt) Derivativo cristalino de morfinan de 6,7-insaturado-7-carbamoil, e método para produzir o mesmo
EP2579284A4 (en) Capacitor and process for producing same
EP2608230A4 (en) Capacitor, and method and program for manufacturing same
EP3156413A4 (en) Ganirelix precursor and method for preparing ganirelix acetate by using anirelix precursor
EP2692738A4 (en) ESTER COMPOUND OF CELLULOSIC DERIVATIVE AND METHOD FOR PREPARING THE SAME
EP2657223A4 (en) METAL-SALEN COMPLEX COMPOUND AND PROCESS FOR PRODUCING THE SAME
EP2401278A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF A CARBAPENEM ANTIBIOTICS
EP2677047A4 (en) Method for collection of ruthenium or ruthenium compound
PL2216455T3 (pl) Element łączący dla drewnianej konstrukcji zespolonej, drewniana konstrukcja zespolona i sposób jej wytwarzania
EP2719695A4 (en) AZOLE DERIVATIVE, PROCESS FOR PRODUCING AZOLE DERIVATIVE, AND INTERMEDIATE COMPOUND
PL3586632T3 (pl) Pochodne 10H-benzo[g]pterydyno-2,4-dionu, sposób ich wytwarzania i ich zastosowanie
HK1219269A1 (zh) 化合物及其生產方法，以及用於生產磷酸奧司他韋的方法
IL215128A0 (en) Method for producing alcohol compound
IL227590B (en) A method for producing derivatives of 1-h-pyrrolidine-4,2-dione
EP2813501A4 (en) PROCESS FOR PREPARING A 4-BENZYL-1-METHYL-6-OXABICYCLO [3,2,0] HEPTIDE SERIVATE
HK1187892A1 (zh) 硫代酰胺化合物及生產該化合物、 -氨乙基- -二噁烷- -基 乙酸酯衍生物和阿托伐他汀的方法
EP3095777B8 (en) Linezolid intermediate and method for synthesizing linezolid
PL2723742T3 (pl) Pochodne 10H-benzo[g]pterydyno-2,4-dionu, sposób ich wytwarzania i zastosowanie
EP2719681A4 (en) METHOD FOR PRODUCING A CYCLOPENTANONE COMPOUND AND INTERMEDIATE PRODUCT THEREOF
EP2543658A4 (en) PROCESS FOR PRODUCING A-ACYLOXYCARBONYL COMPOUND AND NO-ACYLOXYCARBONYL COMPOUND
HK1174031A1 (zh) 噁唑化合物的合成中間體及其製備方法
EP2420504A4 (en) METHOD FOR PRODUCING A MAKROLIDE COMPOUND AND INTERMEDIATE PRODUCT THEREOF
EP2778164A4 (en) PROCESS FOR THE PRODUCTION OF 4-BENZYL-1-METHYL-6-OXABICYCLO [3,2,0] HEPTANE DERIVATIVE AND PROCESS FOR THE PRODUCTION OF AZOLE DERIVATIVE

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210218